Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of ...

New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Registered dietitian Ayla Barmmer told The Post that about 15% of her patients taking GLP-1 medications have struggled to ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S.

ResMed Inc. ( ASX: RMD) shares are back in form — up more than 75% since bottoming out in October 2023.

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...